MACROLIDES AS ANTI-INFLAMMATORY AGENTS Field of the Invention Provided herein are macrolide derivatives that can be useful in treating or preventing inflammatory diseases. Also provided are pharmaceutical compositions comprising one or more macrolide derivatives optionally together with one or more pharmaceutical ly acceptable carriers, excipients, diluents or mixtures thereof, as well as methods for treating or preventing inflammatory diseases. Background of the Invention Macrolides are known to be effective bacteriostatic and bactericidal agents, used for the treatment of range ol bacterial infections. They are effective against gram positive and some gram-negative bacteria, also particularly against atypical pneumonia organisms. Besides, several studies have proved that macrolides are significantly effective in alleviating inllammatory responses and are known to be useful in mitigation of asthma since three decades (Itkins, I.H. Journal of Allergy, 45, 146-62 (1970)). Erythromycin A derivatives have been shown to possess in vitro anti¬inflammatory properties (IM.T. Labro, ./. Anlimicrob. Chemother., 41 (suppI B), 37-46, (1998)). Macrolides, particularly 14-membered ring macrolides, such as erythromycin and clarithromycin, have been shown to reduce the production of endothelin-1, a bronchoconstrictor, in a fashion similar to that of corticosteroids. Roxithromycin was found to be more potent than azithromycin and clarithromycin, while erythromycin showed the least anti-intlammatory activity (D.Wales, Thorax, 54 (SuppI 2), 558-562, (1999)). The potency of roxithromycin is owed to the better cell penetration. Inflammation is the first response of the immune system to infection or irritation. The inflammatory response begins with a release of inflammatory chemicals into the extracellular fluid. Various leukocytes are involved in the initiation and maintenance of inflammation. Neutrophils, eosinophils and monocytes are phagocytic in nature. Along with basophils they secrete leukotrienes, prostaglandins, histamine and other chemicals that promote inflammation. The leukocytes are further stimulated to maintain inflammation through lymphocytes: T cells, B cells, and antibodies. Mast cells, also release potent inflammatory mediators, such as histamine proteases, chemotactic factors, cytokines and metabolites of arachidonic acid, in response to activation of stretch receptors; macrophages release TNF-α, IL-I in response to activation of toll-like receptors. Increased permeability of blood vessels, increased blood flow, migration and accumulation of white blood cells are factors that contribute to the formation of inflammatory exudate, which accumulates in the interstitial spaces in the area of injury and results in heat, swelling, redness and pain. Roxithromycin has been shown to interfere with the production and/or release of inflammatory substances, which can be as active as some non-steroidal anti-inflammatory agents (e.g., nimesulide and indomethacin). Patients with diffuse panbronchiolitis have shown distinct improvement after treatment with macrolides. The 5-year survival rate of 55 % has increased to 94 % survival rate of 10 years. Macrolides can be effectively used in the prophylaxis and/or treatment of respiratory diseases viz. bronchitis, bronchiectasis, rhinitis, cystic fibrosis, emphysema, asthma, pneumonia, sinusitis, tonsillitis, chronic obstructive pulmonary disease or adult respiratory distress syndrome; renal diseases viz. glomerulonephritis (with and without nephritic syndrome); autoimmune diseases viz., rheumatoid arthritis, gout, autoimmune thyroiditis, autoimmune bullous dermatoses, multiple sclerosis or systemic lupus erythematosus; skin diseases viz., psoriasis, eczema, allergic dermatitis, neurodermatitis, or pruritis; cardiovascular diseases viz., myocardial ischemia, congestive heart failure or atherosclerosis; inflammatory bowel disease viz., Crohn's disease, ulcerative colitis, or colitis, others which include, Reiter's syndrome, leukocytoclastic vasculitis, conjunctivitis, uveoretinitis, septic shock, rheumatoid spondylitis, osteoarthritis, septic arthritis or inflammation associated with organ transplant rejection. Inflammation associated with smoking and other environmental factors is also encompassed. PCT Publication No. WO 05/030786 discloses 3'-N-substituted-3-O-substituted erythronolide A derivatives as antibacterial agents. PCT Application No. PCT/US2005/ 027875 discloses ketolide derivatives as antibacterial agents. PCT Publication Nos. WO 06/035301, WO 06/013409 and WO 06/0461 12 disclose macrolides as antibacterial agents. U.S. Patent No. 6,455,576 discloses 3'-des-dimethylamino-9-oxyimino macrolides having anti-inflammatory activity. PCT Publication No. WO 02/087596 discloses novel therapeutic indication of azithromycin for treatment of non-infective inflammatory diseases. PCT Publication No. WO 04/005310 discloses new compounds, compositions and methods for treatment of inflammatory diseases and conditions. PCT Publication No. WO 04/005309 discloses novel non-steroidal anti-inflammatory substances, compositions and methods for their use. Antiinflammatory effects of macrolide have been described in the literature. For example, F.Scaglione in, J. Anihmcioh. Chemother. 41, Suppl.B, 47-50 (1998) describes the comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J.Med.Chem. 47, 4950-4957, (2004) describes the anti¬inflammatory activity of macrolide MLD987 for inflammatory lung diseases. The existing macrolides are highly effective antibacterial agents, which makes it difficult to use them in the treatment of inflammatory diseases. Thus, there remains a need for novel macrolides as anti¬inflammatory agents, devoid of antibacterial activity. Summary of the Invention Accordingly, provided are macrolide derivatives for treating or preventing inflammatory diseases or hsorders, wherein the macrolide derivatives are compounds having the structure of Formula I, pharmaceutically acceptable salts, pharmaceutically acceptable solvates, polymorphs, prodrugs, stereoisomers, tautomeric forms, N-oxides and metabolites thereof, wherein: Y can be hydrogen, halogen, cyano or alkyl; Q can be oxo, thio, -O-(C=T)R:', wherein T can be oxygen or sulfur and R5can be alkyl, alkoxy, aryl or heteroaryl: K1 can be hydrogen or a hydroxy protecting group; R2 and R3 can be independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, aralkyl, (ncterocycle)alkyl or COR6 wherein R6 can be hydrogen, alkyl, aryl or aralkyl, with the provisio that R2 and /?'' simultaneously are not methyl; IV can be hydrogen, alkyl or -(CH2VR7-, wherein q is an integer from 1 to 4; and R7 can be no atom {i.e.. a bond), alkenyl or alkynyl; Z can be O, S. NOR6 (wherein R6 is the same as defined earlier); U and V can be independently hydrogen, hydroxy, OR1, NH(CH2)R8, wherein R1 is the same as defined earlier and R8 can be aryl or heteroaryl; or U and V when taken together can also form a ring of Formula A or Formula B. (Formula Removed) wherein W can be alkenyl, -G(CH2)mJ-, -CRV0, -NR9- or -SO2; wherein G can be no atom, -CO, -CS or -SO2; m can be an integer of from 0 to 6; R9and R10can be independently hydrogen or alkyl; J can be no atom. -CR9R10 or N(Rl2)(CH2)m; wherein Rl2can be hydrogen, alkyl, alkylene, alkynyl, COR11 or -(CH2)ni-R11 wherein R11 can be alkyl, aryl or heterocycle; and m, R9 and R10 are the same as defined earlier: R can be hydrogen, aryl or heterocycle; T is as defined earlier; R4 can be alkyl. alkenyl or alkynyl. Such compounds may include one or more of the following embodiments. For example in one embodiment, provided herein are macrolide derivatives having the structure of Formula la, (Formula Removed) wherein Y is hydrogen or halogen and R , R , R , R', Z, U, V, T and R are the same as defined for the compound of Formula I above. b. wherein Y is hydrogen or halogen, and R1, R2, R3, R', Z, U and V are the same as defined for the In another embodiment, provided herein are macrolide derivatives having the structure of Formula rein Y is hydrogen or hi compound of Formula 1 above. (Formula Removed) In yet another embodiment, provided herein are macrolide derivatives having the structure of Formula 2, (Formula Removed) and pharmaceutical ly acceptable salts, pharmaceutically acceptable solvates, polymorphs, prodrugs, stereoisomers, tautomeric forms, N-oxides or metabolites thereof, wherein Y can be hydrogen or methyl R1, R', and Z are the same as defined for Formula I and R can be aryl or heterocycle. Also provided herein are compounds for treating or preventing inflammatory diseases, including for example: )-O-(2-lluoiophenyl)acetyl-5-O-[3'-N-desmethyl-3'-N-(4-fluoro)benzyl]desosaminyl-6-O-methyl erythronolide A (Compound No. I), 3-O-(3-Fluorophenyl)acetyl-5-O-[3'-N-desmethyl-3'-N-cyclopropyl)desosaminyl-6-O-methyl erythronolide A (Compound No. 2), 3-O-(4-Fluorophenyl)acetyl-5-O-[3'-N-desmethyl-3'-N-(3-hydroxy)benzyl] desosaminyl-6-O-methyl erythronolide A (.Compound No. 3), 3-O-(4-Fluorophenyl)acetyl-5-O-(3'-N-desmethyl-3'-N-propargyl)desosaminyl-6-O-methyl erythronolide A (Compound No. 4), 3-O-(3-Fluorophenyl)acetyl-5-O-(3'-N-desmethyl-3'-N-allyl)desosaminyl-6-O-methyl erythronolide A (Compound No. 5). 3-O-(4-Fluorophenyl)acetyl-5-O-(3'-N-desmethyl-3'-N-allyl)desosaminyl-6-O-methyl erythronolide A (Compound No. 6), 3-O-(2-Fluorophenyl)acetyl-5-O-(3'-N-desmethyl-3'-N-propargyl)desosaminyl-6-O-methyl erythronolide A (Compound No. 7), 3-O-(3-Fluorophenyl)acetyl-5-O-(3'-N-desmethyl-3'-N-propargyl)desosaminyl-6-O-methyl erythronolide A (Compound No. 8). 3-O-(2-Fluorophenyl)acetyl-5-O-(3'-N-desmethyl-3'-N-allyl)desosaminyl-6-O-methyl erythronolide A (Compound No. 9). 3-O-(4-F!uorophenyl)acetyl-5-O-(3'-N-desmethyl-3'-N-(4-nitro)benzyl)desosaminyl-6-O-methyl erythronolide A (Compound No. I 0), 3-O-(4-Nitrophenyl)acetyl-5-O-(3'-N-desmethyl-3'-N-ethyl)desoaminyl-6-O-methyl erythronolide A (Compound No. I i), 3-O-(2-Pyridyl)acetyl-5-O-(3'-N-desmethyl-3'-N-cycIopropylmethyl)desosaminyl-6-O-methyl erythronolide A (Compound No. 12), 3-O-(2-Naphthyl)acetyl-5-O-(3'-N-desmethyl-3'-N-benzyl)desosaminyl-6-O-methyl erythronolide A (Compound No. 13). 3-O-(2.4-Difluorophenyl)acetyl-5-O-(3'-N-desmethyl-3'-N-benzyl)desosaminyl-6-O-methyl erythronolide A (Compound No. |4). 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((4-(pymolo-(2,3-b)-pyridin-l-yl)-butyl)-imino)]erythromycin A(Compound No. 15), 11,12-Dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-ethyl)-6-O-methyl-12,l 1-|oxycaibonyl-((4-(3H)-imidazol-[4,5-b]pyridin-3-yl)-butyl)-imino]erythromycin A(Compound No. 16), 11.12-Dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-ethyl)-6-O-methyl-12,11 -[oxycarbonyl-((4-( 11 l)-imidazol-[4,5-b]pyridin-l-yl)-butyl)-imino]- erythromycin A(Compound No.17), 11,12-Dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-ethyl)-6-O-methyl-12,11 -[oxycarbonyl-((4-pynolo-[2,3-b|pyridin-l-yl)-butyl)imino]erythromycin A (CompoundNo. 18), 1 l,12-Dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-ethyl)-6-O-methyl-12,11-|oxycaibonyl-((4-indol-l-yl)-butyl)-imino]erythromycin A(Compound No. 19), 11,12-Dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-ethyl)-6-O-methyl-12,11 -[oxycarbonyl-((4-(4-phenyl)-imidazol-l-yl)-butyl)-imino]erythromycin A(Compound No. 20), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-l2, 11-[oxycarbonyl-((N"-methyl-N'-quinolin-4-ylmethyl)-2-aminoethyl)-imino]erythromycin A(Compound No.21), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,1 1 - [oxycarbonyl-((N'-methyl-N'-pyridine-3-ylmethyl)-2-aminoethyl)-imino]erythromycin A(Compound No. 22), 2α-Fluoro-5-()-(3'-N-desmethyl-3'-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((N'-methyl-N-pyridine-4-ylmethyl)-2-aminoethyl)-imino]erythromycin A(Compound No. 23), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((N'-meihyl-N'-pyiidine-2-ylmethyl)-2-aminoethyl)-imino]erythromycin A (Compound No. 24), 2α-Fluoro-5-O-(3'-N-desrnethyl-3'-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((4-((4-phenyl)-imidazol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 25), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11-[oxycarbonyl-((4-((5-iiiuo)-indol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 26), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-11,12-dideoxy-3-O-dectadinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((4-((11 i)-imidazo (4,5-c]pyridin-l-yl)-butyl)-imino)]erythromycin A (Compound No. 27), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-1 l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,1 l-[oxycarbonyl-((4-(benzotriazol-2-yl)-butyl)-imino)]erythromycin A (Compound No. 28), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12, 1 l-[oxycarbonyl-((4-((3H)-imidazo-[4,5-c]pyridin-3-yl)-butyl)-imino)]erythromycin A (Compound No. 29), 2α-Fluoro-5-C)- (3'-N-desmethyl-3'-N-ethyl)-l l,l2-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l l-[oxycarbonyl-((4-(pyntldin-4-yl)-butyl)-imino)]erythromycin A (Compound No. 30), 2α-Flioro-5-O- (3'-N-desmethyl-3'-N-ethyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l 1 -[oxycarbonyl-((4-(pynclin-3-yl)-butyl)-imino)]erythromycin A (Compound No. 31), 2α-F luoro-5-O-(3'-N-desmethyl-3'-N-allyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((4-(benzotnazol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 32), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-allyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l l-[oxycarbonyl-((4-(benzoimidazol-1 -yl)-butyl)-imino)]erythromycin A (Compound No. 33), 2α-Fluoro--5-O-(3'-N-desmethyl-3'-N-alIyl)-l l,l2-dide0xy-3-O-decladinosyl-6-O-methyl-3-oxo-12, I l-[oxycarbonyl-((4-((3H)-imidazo-|4,5-b]pyridin-3-yl)-butyl)-imino)]erythromycin A (Compound No.34), 2α-Fluoio-5-O-(3'-N-desmethyl-3'-N-isopropyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l 1-bonyl-((4-((4-phenyl)-imidazol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 35), 2α-Fluoro--5-O-(3'-N-desmethyI-3'-N-isopropyl)-1 1,12-dideoxy-3-O-decIadinosyl-6-O-methyl-3-oxo-12,11-|i)\ycarbonyl-((4-(benzotriazol-2-yl)-butyl)-imino)]erythromycin A (Compound No. 36), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-isopropyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11-[oxycarbonyl-((4-(indol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 37), I l,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-ethyl)-6-O-methyl-12,ll-[oxycarbonyl-((Nl-methyl-Nl-pyridin-2-ylmethyl)-2-aminoethyl)-imino]erythromycin A (Compound No. 38), 1 l.l2-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-ethyl)-6-O-methyl-l2,ll-[oxycarbonyl-((N'-methyl-N'-quinolin-4-ylmethyl)-2-aminoethyl)-imino]erythromycin A (Compound No. 39), ! !.l2-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-ethyl)-6-O-methyl-12,ll-[oxycarbonyl-((N,-methyl-Nl-pyridin-4-ylmethyl)-2-aminoethyl)-imino]erythromycin A (Compound No. 40), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-allyl)-l l,l2-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l l-[oxycarbonyl-(( N'-nielhyl-N'-pyridine-2-ylmethyl)-2-aminoethyl)-imino]erythromycin A (Compound No. 41), 2α-Fluoio-5-O-(3'-N-desmethyl-3'-N-allyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((N'-niethyl-N'-pyridine-3-ylmethyl)-2-aminoethyl)-imino]erythromycin A (Compound No. 42), 2α-Flioro-5-O-(3'-N-desmethyl-3'-N-allyl)-l l,l2-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l l-[oxycarbonyl-((N'-nicihyl-N-c|uiiioline-4-ylmethyl)-2-aminoethyl)-imino]erythromycin A (Compound No. 43), 5-O-(3'-N-desmethyl-3'-N-ethyl)desosaminyl-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-l2, 1 l-[oxycarbonyl-ridin-3-yl-methyl-benzimidazol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 44), 5-O-( ''-N-desmethy 1-3"-N-ethyl)desosaminyl-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((4-(4-pyridin-3-yl-imidazol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 45), 5-U-(3'-N-desmethyl-3'-N-ethyl)desosaminyl-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((4-(imidazo[4,5-b]pyridin-l-yl)-butyl)-imino)]erythromycin A (Compound No. 46), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-isopropyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l 1-[oxycarbonyl-((4-((5-mtro)-indol-l-yl)-butyl)-imino)]erythromycin A(Compound No. 47), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-l 2,11 -[oxycarbonyl-((4-((5-tluoro)-indol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 48), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((4-(benzotriazol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 49), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12, 11 - [oxycarbonyi-((4-((2-methyl)-benzoimidazol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 50), 2α-Fluoro-5-O- (3'-N-desmethyl-3'-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((4-tpyi klm-2-yl)-butyl)-imino)]erythromycin A (Compound No. 51), 2α-Fluoi'o-5-O-(3'-N-desmethyl-3'-N-allyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12, 1 l-[oxycarbonyl-((4-((2-methyl)-benzoimidazol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 52), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-2-fluoroethyl)-l l,12-dideoxy-3-O-decladinosyI-6-O-methyl-3-oxo-12,U-|oxycaibonyl-((4-((3H)-imidazo[4,5-b]pyridin-3-yl)-butyl)-imino)]erythromycin A (Compound No. 53), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-allyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-l 2,1 1 -[oxycarbonyl-((4-i(4-phenyl)-iniida/.ol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 54), 2-dideoxy-3-O-decladinosyl-3-O-(3-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,11 -[oxycarbonyl-((4-(4-pyridin-3-yl)-imidazol-l-yl)-butyl)-imino]erythromycin A (Compound No. 55), 2α-iluoio-5-O-(3'-N-desmethyl-3'-N-cyclopropyl methyl)-1 l,12-dideoxy-3-O-decladinosy!-6-O-methyl-3-oxo-12,l 1-|oxycarbonyl-((4-((4-phenyl)-imidazol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 56), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-cyclopropyl methyl)-! l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-l2,l 1-[oxycarbonyl-((4-(benzotriazol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 57), 2α-Fkioro-5-O-(3'-N-desmethyl-3'-N-cyclopropyl methyl)-1 l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l 1-[oxycarbony-((4-((4-pyridin-3-yl)-imidazol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 58), 2α-Fluoro-5-O-(3'-N-desmethy l-3'-N-acety I)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((4-((4-phi'nvl)-imidazol-l-yl)-butyl)-imino)]erythromycin A (Compound No. 59), 2α-Fluoio-5-O-(3'-N-desmethyl-3'-N-ethyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-l2,l l-[oxycarbonyl-((N'-pyndinL'-3-ylmethyl)-2-aminoethyl)-imino]erythromycin A (Compound No. 60), 2α-Fluoro-5-O- (3'-N-desmethyl-3'-N-allyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((N' itcetyl-N'-pyridine-3-ylmethyl)-2-aminoethyl)-imino]erythromycin A (Compound No. 61), 2α-Fluoio-5-O- (3'-N-desmethyl-3'-N-allyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l l-[oxycarbonyl-((N'-pyiidine-3-ylmethyl)-2-aminoethyl)-imino]erythromycin A (Compound No. 62), 11,12-dideoxy-3-O-decladinosyl-3-O-(3-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,11 -[oxycarbonyl-((4-(3ll)imidazo[4,5-b]pyridin-3-yr)-butyl)-imino]erythromycin A (Compound No. 63), 11,12-dideoxy-3-O-decladinosyl-3-O-(3-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,11 -[oxycarbonyl-( l-plic!i_vl)-imidazol-l-yl)-butyl)-imino]erythromycin A (Compound No. 64), I 1. 12-didcoxy-3-O-decladinosyl-3-O-(4-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-ethyl)-6-O-methyl-12,l l-[oxycarbonyl-((4-(3H)iniidazo[4,5-b]pyridin-3-yl)-butyl)-imino]erythromycin A (Compound No. 65), I l,12-dideoxy-3-O-decladinosyl-3-O-(4-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-ethyl)-6-O-methyl-l2,ll-lo\ycaibonyl-((4-benzotriazol-l-yl)-butyl)-imino]erythromycin A (Compound No. 66), 2α-Fluoro-5-O- (3'-N-desmethyl-3'-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((4-(quinolin-8-yl)-butyl)-imino)]erythromycin A(Compound No. 67), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-cyclopropyl methyl)-1 l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l 1-[oxycarbonyl-((4-(( I H)-imidazo[4,5-bjpyridin-l-yl)-butyl)-imino)] erythromycin A (Compound No. 68), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-acetyl)-l l,12-dideoxy-3-O-decIadinosyl-6-O-methyl-3-oxo-12,i I-[oxycarbonyl-((4-[oxycarbonyl-3-vl)-imidazo)-l-yl)-butyl)-imino)]erythromycin A (Compound No. 69), 1 l,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-propargyl)-6-O-methyl-12,11-[oxycarbonyl-((4-benzoimidazo-l-yl)-butyl)-imino]erythromycin A (Compound No. 70), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-ethyl)-6-O-methyl-12,ll-ycarbtinyl-((4-benzotriazol-l-yl)-butyl)-imino]erythromycin A (Compound No. 71), 1 l,l2-dideoxy-3-O-decladinosyl-3-O-(3-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-ethyl)-6-O-methyl-l2,ll-[oxycarbony-((4-benzotriazol-l-yl)-butyl)-imino]erythromycin A (Compound No. 72), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-allyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12, 1 l-[oxycarbonyl-((4-((4-pyridin-2-yl-lH-imidazol-l-yl)-butyl)-imino))]erythromycin A (Compound No. 73), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l 1-[oxycarbonyl-((4-((4-plienyl-pyrazol-l-yl)-butyl)-imino))erythromycin A (Compound No. 74), 2α-Fluoro-5-O-(.3'-N-desmethyl-3'-N-allyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l l-[oxycarbonyl-((3-pynolol2,3-bjpyridin-l-yl)-propyl)-hydrazo)]erythromycin A (Compound No. 75), 2α-Fluoro-5-O-(3'-N-desmethyl-3 '-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-(i4-((iazol-2-yl)-butyl)-imino))]erythromycin A (Compound No. 76), I !. 12-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-ethyl)-6-O-methyl-12,l 1-[oxycarbonyl-(4--9H-purin-9-yl butylimino)]erythromycin A (Compound No. 77), I l,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyI-3'-N-ethyl)-6-O-methyl-12,ll-[oxycarbony-((4-(isoquinolin-5-yl)-butyl)-imino)]erythromycin A (Compound No. 78), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desrnethyl-3'-N-allyl)-6-O-methyl-12,11 -[oxycarbonyl-(4-(6-methylamino-9H-purin-9-yl butylimino)]erythromycin A (Compound No. 79), 11,12-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,11-[oxycarbonyl-(4-(6-methylammo-9H-purin-9-yl butylimino)]erythromycin A (Compound No. 80), ! LI2-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,ll-[oxycarbony(l-allyl-3-(9-(4-amino-butyl)-9H-purin-6-yl)-urea)-imino)]erythromycin A (Compound No. 81), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,ll-[oxycarbonyl-((4-[oxycarbony-2-yl-l H-imidazol-lyl)-butyl)-imino)]erythromycin A (CompoundNo. 82), 1 l,l2-dideoxy-3-O-decladinosyl-3-O-(3-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,ll-|o\ycarbonyl-((4-( I H-imidazol[4,5-c]pyridin-l-yl)-butyl)-imino)]erythromycin A (Compound No. 83), I l,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,ll-[oxycarbonyl-(3-(4-(thiophen-3-yl)-lH-imidazol-lyl)-propyl)-hydrazo)]erythromycin A (Compound No. 84). 1 l,12-dideoxy-3-O-decadinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,l 1-[oxycarbony-(3-purin-9-yl)-propyi)-hydrazo)]erythromycin A (Compound No. 85), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbony-((3-purin-9-yl)-propyl)-hydrazo)]erythromycin A (Compound No. 86), 1 l,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbonyl-(3-isi)[oxycarbony-5-yl)-propyl)-hydrazo)]erythromycin A (Compound No. 87), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-hydrazo|erythromycin A (Compound No. 88), 11,12-dideoxy-3-O-decladinosyl-3-O-(3-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,ll-|oxycarbonyl-((4-(isoquinolin-5-yl)-butyl)-imino)]erythromycin A (Compound No. 89), 111 2-didcoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,11-[oxycarbonyl-[oxycarbony-2-yl-l H-imidazol-lyl)-butyl)-imino)]erythromycin A (Compound No. 90), I 1. 12-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,11-[oxycarbonyl-[oxycarbony-3-yl-l H-imidazol-lyl)-butyl)-imino)]erythromycin A (Compound No. 91), I 1, l2-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l l-[oxycarbonyl-((4-(4-t"uruii-3-yl-IH-imidazol-lyl)-butyl)-imino)]erythromycin A (Compound No. 92). I l,12-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyi)-5-O-(3'-N-desmethyl-3'-N-alIyI)-6-O-methyl-12,l I - [oxycarbonyl-(3-(4-(furan-3-yl)-l H-imidazol-l-yl)propyl)-hydrazo)]erythromycin A (Compound No. 93), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyI)-6-O-methyl-12,ll-[oxycarbonyl-(3-(4-(furan-3-yl)-l H-imidazol-l-yl)propyl)-hydrazo)]erythromycin A (Compound No. 94), 1 l,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-aIlyl)-6-O-methyl-12,ll-[oxycarbonyl-(3-(4-(thiophen-2-yl-IH-imidazol-l-yl)-propyl)-hydrazo)]erythromycin A (Compound No. 95), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-allyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12, 1 l-[oxycarbonyl-((3-3-yl-imidazol-l-yl)propyl)-hydrazo)]erythromycin A (Compound No. 96), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12, 11-[oxycarbonyl-((4-l(4-furan-2-yl-l H-imidazol-l-yl)-butyl)-imino))]erythromycin A (Compound No. 97), 2α-Fluoro-5-O-(3'-N-desmethyl-3,-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12, 11 -[oxycarbonyl-((4-((4-thiophen-2-yl-1 H-imidazol-1 -yl)-butyl)-imino))]erythromycin A (Compound No. 98), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,l 1-[oxycarbonyl-(4-(4-(thiophen-2-yl)-pyrazol-l-yl)-butylimino)]erythromycin A (Compound No. 99), 1 l,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,ll-[oxycarbonyl-4-([l,4']-bipyrazol-l'-yl)-butylimino)]erythromycin A (Compound No. 100), 11.1 2-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,11-[oxycarbonyl-1 .Mimidazol4,5-b|pyridin-l-yl)-propyl)-hydrazo)]erythromycin A (Compound No. 101), 1 l,l2-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbonyl-(3-( imicla/o[4,5-b]pyridin-3-yl)-propyl)-hydrazo)]erythromycin A (Compound No. 102), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-11,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,11 -[oxycarbonyl-((3-(3-thioplien-j-yl-phenoxy)-propyl)-imino)]erythromycin A (Compound No. 103), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbonyl-((3-(3--3-yl-phenoxy)-propyl)-imino)]erythromycin A (Compound No. 104), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,11 -[oxycarbonyl-(4-(4-(2-thiazolyl)-imidazol-l-yl)-butylimino)]erythromycin A (Compound No. 105), I l,12-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbonyl-(4-( t-(thiazol-2-yl)-imidazol-l-yl)-butylimino)]erythromycin A (Compound No. 106), 1 1. l2-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbonyl-(4-(4-(lfan-3-yl)-pyrazol-l-yl)-butylimino)]erythromycin A (Compound No. 107), I l,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbonyl-(4-(4-(thiophen-3-yl)-pyrazol-l-yl)-butylimino)]erythromycin A (Compound No. 108), I U2-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbonyl- (4-(4-(thiophen-3-yl)-pyrazol-l-yl)-butylimino)jerythromycin A (Compound No. 109), II 12-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbonyl- t,4-(4-(lfiran-3-yl)-pyrazol-l-yl)-butylimino)]erythromycin A (Compound No. 110), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,11 -[oxycarbonyl-(4-( I H-imidazol[4,5-b]pyridin-2-yl )-butylimino)]erythromycin A (Compound No. Ill), 11.12-clideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,11 -[oxycarbonyl-(4-(4-teirazol-l-yl)-imidazol-l-yl)-butylimino)]erythromycin A (Compound No. 112), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-desosaminyl-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l 1-[oxycarbony-((4-(3H-lmidazo[4,5-b]pyridine-2-yl)-butyl)-imino)erythromycin A (Compound No. 113), 11,12-dideoxy-3-O-decIadinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbony-(4-( I H-benzimidazol-2-yl)-butylimino)]erythromycin A (Compound No. 114), I U2-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbony-(3-( J3-[4-(6-tUioro-pyridin-3-yl-imidazol-l-yl] propyl}hydrazo]erythromycin A (Compound No. 115), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-desosaminyl-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l 1-[oxycarbony-((4-(4-Tetrazol-l-yl-imidazol-l-yl)-butyl)-imino)erythromycin A (Compound No. 116), 1 l,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,U-[oxycarbony-(3-({3-[4-(6-fluoro-pyridin-3-yl-imidazol-l-yl] propylJhydrazo] erythromycin A (Compound No. 117), 2α-Fluoio-5-O-(3'-N-desmethyl-3'-N-ethyl)-desosaminyl-ll,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l 1-|'oxycarbonyl-((4-( I H-Benzoimidazol-2-yl)-butyl)-imino)erythromycin A (Compound No. 118), 1 l,l2-dideoxy-3-O-decladinosyl-3-O-(2-methyi propanoyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbony-(4-(4-imidazol[4,5-b]pyridin-l-yl)-butylimino)]erythromycin A (Compound No. 119), I U2-dideoxy-3-O-decladinosyl-3-O-(2-methyl propanoyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-|o\ycaibonyl-(4-(6-amino-9H-purin-9-yl)butylimino)]erythromycin A (Compound No. 120), 11,12-clideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l l-[oxycarbonyl-(4-|4-(.pyrazol-l-yl)-imidazol-l-yl)butylimino]erythromycin A (Compound No. 121), I l,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-alIyl)-6-O-methyl-12,ll-[oxycarbony-(4-([l,4']-biimidazol-r-yl)butylimino)]erythromycin A (Compound No. 122), 11,12-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbony-(4-([ 1,4']-biimidazol-r-yl)butylimino)]erythromycin A (Compound No. 123), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-methylpropanoyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,l 1-[oxycarbony-(4-(imidazo[4,5-A]pyridin-3-yl)butylimino)]erythromycin A (Compound No. 124), 11.12-dideo\y-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,11 -[oxycarbonyl-[oxycarbony-l-yl)-imidazol-l-yl)butylimino)]erythromycin A (Compound No. 125), I i.l2-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbonyl-(4-(4-i 1H-imidazo[4,5-c]pyridin-2-yl)butylimino)]erythromycin A (Compound No. 126), I U2-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbonyl-(4-(4-(1H-imidazo[4,5-c]pyridin-2-yl)butylimino)]erythromycin A (Compound No. 127), I I ,l2-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l I-[oxycarbonyl-(4-(4-phenyl-thiazol-2-yl)butylimino)]erythromycin A (Compound No. 128), I 1. 12-dideoxy-3-O-decladinosyl-3-O-(3-pyridyi acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,11 - [oxycarbonyl-(3-(3-(4-pyrazol-1 -yl)-imidazol-1 -yl)-propyl)-hydrazo]erythromycin A (Compound No. 129), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,ll-[oxycarbony-3-((3-( I H-imidazo[4,5-b]pyridine-l-yl)- propyl)-hydrazo)]erythromycin A (Compound No. 130), 11,12-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,11-[oxycarbonyl-(4-(4-(oNazol-5-yl)-imidazol-l-yl)butylimino)]erythromycin A (Compound No. 131), 11,12-d?deoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbonyl-(4-(4-iiriida7.ol-l-yl)-pyrazol-l-yl]butylimino)]erythromycin A (Compound No. 132), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,1 l-[oxycarbonyl-(4-(4-imidazol-l-yl)-pyrazol-l-yl]butylimino)]erythromycin A (Compound No. 133), 11,12-dideox>-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,l 1-[oxycarbony-(4-[3,3']-bithiophenyl-5-yl)butylimino)]erythromycin A (Compound No. 134), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,l l-[oxycarbonyl-(4-(5-pyiidin-3-yl)-tetrazol-2-yl)butylimino)]erythromycin A (CompoundNo. 135), 11,12-dideoxy-3-O-decladinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,11 -[oxycarbony-(4-(4-(6-chloropyridin-3-yl)-imidazol-l-ylJbutylimino)]erythromycin A (Compound No. 136), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-methylpropanoyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,ll-[oxycarbony4-(4-(4-(furan-2-yl)-imidazol-l-yl)-butylimino)]erythromycin A (Compound No. 137), I 1.1 2-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,11-[oxycarbonyl-[oxycarbony-bipyrazol-l-yl)-)- propyl)-hydrazo)]erythromycin A (Compound No. 138), 1 l,l2-dideoxy-3-O-decladinosyl-3-O-(3-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,ll-[oxycarbony-(4-(4-(2-methoxy-phenyl)-imidazol-l-yl)-butylimino)]erythromycin A (Compound No. 139), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,ll-[oxycarbony-(4-(4-(2-methoxy-phenyl)-l W-imidazol-l-yl)-butylimino)]erythromycin A (Compound No. 140), I l,12-dideoxy-3-O-decladinosyl-3-O-(3-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-l2,ll-[oxycarbonyl-(4-(4-phenyl-thiophen-2-yl)-butylimino)]erythromycin A(Compound No. 141), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,ll-[oxycarbony-(4-(4-phenyl-thiophen-2-yl)-butylimino)]erythromycin A (Compound No. 142), 11,12-dideoxy-3-O-decladinosyl-3-O-(3-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,ll-[oxycarbonyl-(4-(4-furan-2-yl-thiophen-2-yl)butylimino)]erythromycin A (Compound No. 143), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,ll-[oxycarbonyl-(4-(4-furan-2-yl-thiophen-2-yl)-butylimino)]erythromycin A (Compound No. 144), 11,12dideoxy-3-O-decIadinosyl-3-O-(3-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbonyl-(4-(."i-(4-imecthoxyphenyl)-tetrazol-2-yl)-butylimino)]erythromycin A (Compound No. 145), 11.12-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,11 -[oxycarbonyl-(4-(5-(4-methoxyphenyl)-tetiazol-2-yi)-butylimino)]erythromycin A (Compound No. 146), 11,12-dideoxy-3-O-decladinosyl-3-O-(2-nitrophenyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l 1-[oxycarbony-(4-benzimidazol-l-yi)butylimino)]erythromycin A (Compound No. 147), 1 LI2-dideoxy-3-O-decladinosyl-3-O-(2-pyridylacetyl)-5-O-(3'-N-desmethyl-3'-N-aliyl)-6-O-methyl-12,ll-[oxycarbony-(3-(3-(4-pyrazoI-l-yl]-imidazol-l-yl)- propyl)-hydrazo)]erythromycin A (Compound No. 148), 1 l,12-dideoxy-3-O-decladinosyl-3-O-(2-pyridyl acetyl)-5-O-(3'-N-desmethyl-3'-N-allyl)-6-O-methyl-12,l l-[oxycarbonyl-(4-(-t-( i-aininophenyl)-imidazol-l-yl)-butylimino)]erythromycin A (Compound No. 149), 2α-Fluoro-5-O-(3'-N-desmethyl-3'-N-ethyl)-desosaminyl-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12.11-[oxycarbony-((4-(4-Thiophen-3-yl-pyrazol-l-yl)-butyl)-imino)erythromycin A (Compound No. 150), or 2α-Fluoio-5-O-(3'-N-desmethyl-3,-N-ethyl)-desosaminyl-l l,12-dideoxy-3-O-decladinosyl-6-O-methyl-3-oxo-12,l 1-[oxycarbony-((4-(5-Thiophen-2-yl-pyridin-3-yl)-butyl)-imino)- erythromycin A(Compound No. 151), or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, polymorphs, prodrugs, stereoisomers, tautomeric forms. N-oxides and metabolites thereof. Also provided herein are methods for treating or preventing inflammatory diseases or disorders selected from respiratory diseases, renal diseases, autoimmune diseases, skin diseases, cardiovascular diseases and other diseases which include, Reiter's syndrome, leukocytoclastic vasculitis, conjunctivitis, uveoretinitis, septic shock, atherosclerosis. Crohn's disease, ulcerative colitis, colitis, rheumatoid spondylitis, osteoarthritis or septic arthritis. Also provided herein are pharmaceutical compositions comprising therapeutically effective amounts of one or more compounds of Formula I or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, stereoisomers, polymorphs, N-oxide, prodrugs or metabolites thereof, together with one or more pharmaceutically acceptable carriers, excipients, diluents or mixtures thereof. Such compositions can be used to treat or prevent inflammatory diseases or disorders. Such pharmaceutical compositions may include one or more of the following embodiments. For example in one embodiment, pharmaceutical compositions comprise therapeutically effective amounts of one or more compounds of Formula la or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, stereoisomers, polymorphs. N-oxide, prodrugs or metabolites thereof, together with one or more pharmaceutical!) acceptable carriers, excipients, diluents or mixtures thereof. In another embodiment, pharmaceutical compositions comprise therapeutically effective amounts of OIK or more compounds of Formula lb or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, stereoisomers, polymorphs, N-oxide, prodrugs or metabolites thereof, together with one or more pharmaceutically acceptable carriers, excipients, diluents or mixture thereof. In another embodiment, pharmaceutical compositions comprise therapeutically effective amounts of one or more compounds of Formula 2 or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, stereoisomers, polymorphs, N-oxide, prodrugs or metabolites thereof, together with one or more pharmaceutically acceptable carriers, excipients, diluents or mixture thereof. Also provided are combinations of one or more compounds of Formula I with other active agents in the same or different class or that can be used in therapy of inflammatory diseases to achieve additive or synergistic effects. Such agents may include one or more of steroidal anti-inflammatory agents, non¬steroidal anti-inflammatory agents, COX-2 inhibitors, macrolide immunosuppresives, p-38 MAP Kinase inhibitors, local anesthetics, beta-2 agonists, 5-lipooxygenase inhibitors, phosphodiesterase inhibitors, MMP inhibitors, TNF-alpha inhibitors, caspase inhibitors, VLA4 antagonists, PAF antagonists or mixtures thereof. Also provided herein are combination pharmaceutical compositions for treating or preventing inflammatory diseases or disorders. Other aspect and properties of this matter will be set forth in description which follows, and will be apparent from the description or may be learnt by the practice thereof. However, it should be understood thai the following detailed description is given by way of illustration only, since various changes and modifications within the scope of the invention will become apparent to those skilled in the art and are intended io encompass within the scope herein. Detailed Description of the Invention In accordance with one aspect, provided are macrolide derivatives for treating or preventing the intlamniatory diseases or disorders, wherein macrolide derivatives are compounds having the structure of or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, polymorphs, prodrugs, stereoisomers, tautomeric forms, N-oxides and metabolites thereof, wherein 13 Formula I. (Formula Removed) Y can be hydrogen, halogen, cyano or alkyl; Q can be oxo, thio, -O-(C=T)R5, wherein T can be oxygen or sulfur and R5can be alkyl, alkoxy, aryl or heteroaryl; R1 can be hydrogen or a hydroxy protecting group; R? and R3 can be independently alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycle, aralkyl, (heterocycle)alkyl or COR6, wherein R6 can be hydrogen, alkyl, aryl or aralkyl, with the provisio that R2 unci IV simultaneously are not methyl; R' can be hydrogen, alkyl or -(CH2)q-R7-, wherein q is an integer from 1 to 4; and R7 can be no atom (i.e.. a bond), alkenyl or alkynyl; Z can be O, S, NOR6 (wherein R6 is the same as defined earlier); 11 and V can be independently hydrogen, hydroxy, OR1, NH(CH2)R8, wherein R1 is the same as defined earlier: Rs can be aryl or heteroaryl; or U and V when taken together can also form a ring of Formula A or Formula B, (Formula Removed) wherein W can be alkenyl, -G(CH2)mJ-, -CR9RI0, -NRy- or -SO2; wherein, G can be no atom, -CO, -CS or -SO2; m can be an integer of from 0 to 6; R and Rl0can be independently hydrogen or alkyl; J can be no atom, - CR V" or N(Rl2)(CH2)m; R12can be hydrogen, alkyl, alkylene, alkynyl, COR11 or -(CH2)m-R", wherein Rn can be alkyl. aryl or heterocycle; and m. R9 and R10 are the same as defined earlier; R can be hydrogen, aryl or heterocycle; T is as defined earlier; and R4 can be alkyl, alkenyl or alkynyl. Such compounds can be prepared by, for example, methods described in WO05/030786, WO06/080954, WO06/013409, WO06/035301 and WO06/046112, each of which are incorporated herein b\ reference. In one embodiment, provided herein are macrolide derivatives having the structure of Formula la, (Formula Removed) wherein Y is hydrogen or halogen and R1, R2, R3, R', Z, U, V, T and R5 are the same as defined for the compound of Formula I. In another embodiment, provided herein macrolide derivatives having the structure of Formula lb, (Formula Removed) wherein Y is hydrogen or halogen and R , R, R , R', Z, U and V are the same as defined for the compound of Formula I. In yet another embodiment, provided herein are macrolide derivatives having the structure of Formula 2. (Formula Removed) or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, polymorphs, prodrugs, stereoisomers, tautomeric forms, N-oxides and metabolites thereof, wherein Y can be hydrogen or methyl; R can be arvl or heterocycle; and R1, R', and Z are the same as defined for the compound of Formula I. Hydroxy protecting groups include those known to one of ordinary skill in the art. Hydroxy protecting also include, for example, acetyl, benzoyl, butyldiphenylsilyl, methylthiomethyl or methoxy methyl. AI so provided herein are compounds for treating or preventing inflammatory diseases, including for example, compound no. 1 to compound no. 151, as well as their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, polymorphs, prodrugs, stereoisomers, tautomeric forms, N-oxides and metabolites thereof. The term •"alkyl," unless otherwise specified, refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 20 carbon atoms. This term can be exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl. n-hexyl, n-decyl, tetradecyl, and the like. Alkyl groups may be substituted further with one or more substituents selected from alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy. alkoxy-carbonylamino, azido, cyano, halogen, hydroxy, oxo, thiocarbonyl, carboxy, carboxyalkyl, aryl, heterocyclyl. heteroaryl, arylthio, thiol, alkylthio, aryloxy, nitro, aminosulfonyl, aminocarbonylamino, -NHC(=O)Rr, -NRtRq, -C(=O)NRtRq, -NHC(=O)NRfRq, -C(=O)heteroaryl, C(=O)heterocyclyl, -O-C (=O)NR|Rq {wherein Rt and Rq are independently selected from hydrogen, alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl. aralkyi, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroarylalkyi}, nitro, or -SO R, (wherein R, is alkyl, alkenyl, alkynyl, cycloalkyl, aralkyi, aryl, heterocyclyl, heteroaryl, heteroarylalkyi or heterocyclylalkyl). Unless otherwise constrained by the definition, alkyl substituents may be further substituted by 1-3 substituents selected from alkyl, carboxy, -NRtRq, -C(=O)NRt-Rq, -OC(=--())NR|-Rq, -NHC(=O)NRtRq (wherein Rf and Rq are the same as defined earlier), hydroxy, alkoxy, halogen, CFj, cyano, and -SO2Rb, (wherein Rb is alkyl, alkenyl, alkynyl, cycloalkyl, aralkyi, aryl, heterocyclyl. heteroaryl, heteroarylalkyi or heterocyclylalkyl); or an alkyl group also may be interrupted by I -5 atoms of groups independently selected from oxygen, sulfur or -NRa- {wherein Ra is selected from hulrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, acyl, aralkyl,-C(=O)ORt (wherein Rfisthe same as defined earlier), SO2R4 (where R4 is as defined earlier), or -C(=O)NRtRq (wherein Rt and Rq are as dellned earlier)}. Unless otherwise constrained by the definition, all substituents may be substituted further by 1-3 substituents selected from alkyl, carboxy, -NRfRq, -C (=O)NRfRq, -O-C(=O)NRtRq, NHCOORb (wherein R,. Rq and Rt, are the same as defined earlier), hydroxy, alkoxy, halogen, CF3, cyano, and -SO2Rj (where R, is same as defined earlier); or an alkyl group as defined above that has both substituents as dellned above and is also interrupted by 1-5 atoms or groups as defined above. The term "alkenyl or alkynyl" stands for unsaturated hydrocarbon having two to six carbon atoms. One or more hydrogen of said alkenyl or alkynyl can be replaced by halogen, NHCORb, NHCOORb, CORb, OCORh (wherein Rb is the same as defined earlier). Examples of alkenyl and alkynyl include, but are not limited to, ethylene, propylene, ethynyl, propynyl, and the like. The term "alkoxy" stands for a radical represented by Formula O-alkyl and wherein alkyl is the same as defined above. Examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, and the like. The term •"cycloalkyl" refers to saturated carbocyclic ring having three to seven carbon atoms. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl and cyclopentyl, and the like. The term "halogen" refers to fluorine, chlorine, bromine or iodine. 1 he term "aryl," unless otherwise specified, refers to carbocyclic aromatic groups, for example, phenyl, biphenyl or napthyl ring and the like, optionally substituted with 1 to 3 substituents selected from halogen (e.g., F CI. Br. I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, acyl, aryloxy, CF3, cyano, nitro, COORe (wherein Rcis hydrogen, alkyl, alkenyl, cycloalkyl, aralkyl, heterocyclylalkyl, heteroarylalkyl), NHC(=O)Rf, -NR,Rq. -C(=O)NRtRq, -NHC(=O)NRtRq. -O-C(=O)NRtRq (wherein R, and R<, are the same as defined earlier), -SO^Ri, (wherein Rb is same as defined earlier), carboxy, heterocyclyl, heteroaryl, heterocyclylalkyl, heteroarylalkyl or amino carbonyl amino. The aryl group optionally may be fused with a cycloalkyl group, wherein the cycloalkyl group may optionally contain heteroatoms selected from O, N or S. The term "heteroaryl," unless otherwise specified, refers to an aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group having from 8 to 10 ring atoms, with one or more heteroatom(s) independently selected from N, O or S optionally substituted with 1 to 4 substituent(s) selected from halogen (e.g.. I , CI. Br, I), hydroxy, alkyl, alkenyl, alkynyl, cycloalkyl, acyl, carboxy, aryl, alkoxy, aralkyl, cyano, nitro. hetero- cyclyl, heteroaryl, -NRtRq, CH=NOH, -(CH2)wC(=O)Rg {wherein w is an integer from 0-4 and R, is hydrogen, hydroxy, ORr, NR,Rq, -NHOR, or-NHOH}, -C(=O)NRtRq and -NHC(=O)NRtRq, -SO2Rb,-0-C(=O)NR,RM. -O-C(=O)Rt, -O-C(=O)OR, (wherein Rb, Rf and Rq are as defined earlier, and RZ is alkyl, cycloalkyl. aryl, heteroaryl, heterocyclyl, heteroarylalkyl or heterocyclylalkyl). Unless otherwise constrained by the definition, the substituents are attached to a ring atom, i.e., carbon or heteroatom in the ring. Examples of heteroaryl groups include oxazolyl, imidazolyl, pyrrolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, thiazolyl, oxadiazolyl, benzoimidazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, thienvl, isoxazolyl, triazinyl, furanyl. benzofuranyl, indolyl, benzothiazolyl, or benzoxazolyl, and the like. Hie term 'heterocyclyl," unless otherwise specified, refers to a non-aromatic monocyclic or bicyclic cycloalkyl group having 5 to 10 atoms wherein 1 to 4 carbon atoms in a ring are replaced by heteroatoms selected from O, S or N, and optionally are benzofused or fused heteroaryl having 5-6 ring members and/or optionally are substituted, wherein the substituents are selected from halogen (e.g., F, CI, Br, I), hydroxy, alkyl. alkenyl, alkynyl, cycloalkyl, acyl, aryl, alkoxy, alkaryl, cyano, nitro, oxo, carboxy, heterocyclyl, heteroaryl, -O-C(=O)R,-, -O-C(=O)ORt. -C(=O)NRtRq, SO2Rb, -O-C(=O)NRtRq, -NHC(=O)NRtRq, -NRfRq (wherein Rh R, and Rq are as defined earlier) or guanidine. Heterocyclyl can optionally include rings having one or more double bonds. Unless otherwise constrained by the definition, the substituents are attached to the ring atom, i.e., carbon or heteroatom in the ring. Also, unless otherwise constrained by the definition, the heterocyclyl ring optionally may contain one or more olefmic bond(s). Examples of heterocyclyl groups include oxazolidinyl, tetrahydrofuranyl, dihydrofuranyl, dihydropyridinyl. dihydroisoxazolyl, dihydrobenzofuryl, azabicyclohexyl, dihydroindolyl, pyridinyl, isoindole 1,3-dione, piperidinyl or piperazinyl. The groups "alkyl, aryl, heteroaryl and heterocyclyl" can optionally be substituted with substituent(s) selected from alkyl, haloalkyl, cycloalkyl, cycloalkenyl, cycloalkoxy, aryl, heterocyclyl, heteroaryl, aralkyl, heteroarylalkyl, heterocycloalkyl, halogen, hydroxy, alkoxy, cyano, nitro, aryloxy, haloalkoxy, CORb, C'SRh. C'OORh, S(0)aRh, OCOORb, OCORb, SO2NHRb, NHSO2Rb, NHC0Rb, NHCSRb, (CH)aC(=O)NRcR